The invention relates to an inhibitor of Calcineurin B Homologous Protein 1 (CHP1) for use in a method for the treatment or prevention of a patient suffering from or being at risk of developing a disorder associated with a pathological calcium homeostasis, impaired vesicular trafficking and/or disturbed neuronal and/or neuromuscular synaptic function.